Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539900 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT03539900 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 89 participants.
The verdict
NCT03539900, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This study will test the efficacy of naltrexone HCI and bupropion HCI (NB) versus placebo in patients with binge-eating disorder (BED), with or without obesity.
Interventions
- OTHER Placebo
- DRUG Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2018-04-17 |
| Est. Completion | 2023-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03539900
The ClinicalTrials.gov registry entry for NCT03539900 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03539900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03539900 about?
NCT03539900 is a clinical study titled "Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder". This study will test the efficacy of naltrexone HCI and bupropion HCI (NB) versus placebo in patients with binge-eating disorder (BED), with or without obesity.
What is the current status of trial NCT03539900?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2018-04-17. Estimated completion is 2023-03-22.
What interventions are being tested in trial NCT03539900?
The interventions under investigation include: Placebo (OTHER), Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination (DRUG).
Who is sponsoring clinical trial NCT03539900?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.